{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:40:46Z","timestamp":1764304846479,"version":"3.46.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection are endowed with sustained virological response (SVR) rates &gt;95%. However, HCV cure does not completely eliminate the risk of hepatocellular carcinoma (HCC) development and liver decompensation. The present study investigated the impact of the administered DAA regimen on clinical long-time outcomes after SVR.<\/jats:p>\n                  <jats:p>Matched-pair survival analyses of 5802 chronically HCV infected patients from the German Hepatitis C-Registry compared the incidence of liver-related events 2.5 years after SVR in patients receiving either sofosbuvir (SOF)-based treatment or NS3\/NS4A-protease inhibitor (PI)-containing DAA regimens. Hypothesis driven logistic regression analyses were performed to identify independent predictors for the occurrence of liver-related events.<\/jats:p>\n                  <jats:p>Matched-pair survival analyses revealed a borderline significant difference in the incidence of liver-related endpoints (except of HCC development) in patients receiving SOF-based treatment (4.1%) compared to PI-containing DAA regimens (2.6%) 2.5 years after SVR (p=0.061). Numerically, a trend towards a benefit of PI-based DAA treatment was observed (PI 65 events vs SOF 102 events). Hypothesis driven logistic regression analyses could not confirm SOF-based treatment as an independent predictor for the occurrence of liver-related events after HCV cure (p=0.072, OR=0.670).<\/jats:p>\n                  <jats:p>The incidence of liver-related events 2.5 years after HCV cure did not differ significantly between SOF-based DAA treatment and PI-containing regimens. However, numerically a trend towards a benefit of PI-based DAA treatment was observed. Therefore, a minor effect of the applied DAA regimen on the long-term incidence of liver-related events cannot be excluded.<\/jats:p>","DOI":"10.1055\/a-2543-5205","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:23:53Z","timestamp":1747164233000},"page":"486-496","source":"Crossref","is-referenced-by-count":0,"title":["Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure \u2013 Data from the German Hepatitis C-Registry (DHC-R)"],"prefix":"10.1055","volume":"63","author":[{"given":"Valerie","family":"Ohlendorf","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Serfert","sequence":"additional","affiliation":[{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[{"name":"ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[{"name":"Center for HIV and Hepatogastroenterology, Duesseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine II, University of W\u00fcrzburg Medical Center, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Teuber","sequence":"additional","affiliation":[{"name":"Practice PD Dr. med. G. Teuber, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany"},{"name":"Centre for Individualised Infection Medicine (CiiM), Hannover, Germany"},{"name":"German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Braunschweig, Germany"},{"name":"Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC), Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany"},{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"},{"name":"German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Braunschweig, Germany"},{"name":"Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC), Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1149\/2.030203jes","volume-title":"Global Hepatitis Report 2017. Licence: CC BY-NC-SA 3.0 IGO","author":"World Health Organization","year":"2017"},{"issue":"01","key":"ref3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2049936115585942","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"P Cacoub","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) \u2013 A new age in the treatment of hepatitis C virus infection","volume":"183","author":"U Spengler","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"05","key":"ref5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series\u2606","volume":"73","author":"JM Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"issue":"24","key":"ref6","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"AJ Van Der Meer","year":"2012","journal-title":"JAMA"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/apt.15597","article-title":"Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis","volume":"51","author":"F Ebel","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"LAP Krassenburg","year":"2021","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/5584_2020_604","article-title":"Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review","volume":"1323","author":"E Sagnelli","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"08","key":"ref10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jvh.13546","article-title":"Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting\u2014results from the German Hepatitis C-Registry (DHC-R)","volume":"28","author":"V Ohlendorf","year":"2021","journal-title":"J Viral Hepat"},{"key":"ref11","first-page":"1","article-title":"Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis","volume":"90","author":"J Murtagh","year":"2006","journal-title":"Issues Emerg Health Technol"},{"issue":"02","key":"ref12","first-page":"103","article-title":"Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease","volume":"11","author":"Y Yilmaz","year":"2011","journal-title":"Hepat Mon"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref14","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"CG Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"02","key":"ref15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"PS Kamath","year":"2001","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45409","volume-title":"Released 2019. IBM SPSS Statistics for Windows, Version 26.0","author":"IBM Corp","year":"2019"},{"issue":"02","key":"ref18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"H Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"A Desai","year":"2019","journal-title":"World J Hepatol"},{"issue":"01","key":"ref20","doi-asserted-by":"publisher","first-page":"e13750","DOI":"10.1111\/acel.13750","article-title":"Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal","volume":"22","author":"C Kuehnemann","year":"2023","journal-title":"Aging Cell"},{"issue":"04","key":"ref21","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/jvi.74.4.2046-2051.2000","article-title":"Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3\u2032 Nontranslated Region Are Essential for Virus Replication In Vivo","volume":"74","author":"AA Kolykhalov","year":"2000","journal-title":"J Virol"},{"issue":"05","key":"ref22","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1128\/jvi.79.5.2689-2699.2005","article-title":"Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I","volume":"79","author":"R Sumpter","year":"2005","journal-title":"J Virol"},{"issue":"08","key":"ref23","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1073\/pnas.0408707102","article-title":"Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling","volume":"102","author":"E Foy","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"ref24","doi-asserted-by":"publisher","first-page":"20483","DOI":"10.1074\/jbc.M500422200","article-title":"Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3\/4A protease","volume":"280","author":"JC Ferreon","year":"2005","journal-title":"Journal of Biological Chemistry"},{"issue":"5622","key":"ref25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"E Foy","year":"2003","journal-title":"Science"},{"issue":"12","key":"ref26","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-acting antiviral-induced hepatitis c virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis c","volume":"214","author":"J Hengst","year":"2016","journal-title":"Journal of Infectious Diseases"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.12068","article-title":"New therapeutic strategies in HCV: Polymerase inhibitors","volume":"33","author":"L Gerber","year":"2013","journal-title":"Liver International"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1128\/AAC.01253-16","article-title":"Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk","volume":"60","author":"M Fenaux","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"ref29","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a luoro-2\u2032-\u03b2- C -methyluridine Nucleotide Prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"MJ Sofia","year":"2010","journal-title":"J Med Chem"},{"issue":"08","key":"ref30","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts","volume":"40","author":"A Mangia","year":"2020","journal-title":"Liver International"},{"issue":"06","key":"ref31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/apt.15978","article-title":"Letter: now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority","volume":"52","author":"J Turnes","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"9930","key":"ref32","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"EA Tsochatzis","year":"2014","journal-title":"Lancet"},{"issue":"06","key":"ref33","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","author":"V Calvaruso","year":"2020","journal-title":"J Hepatol"},{"issue":"01","key":"ref34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"HB El-Serag","year":"2016","journal-title":"Hepatology"},{"issue":"02","key":"ref35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2012.03.004","article-title":"Why men are at higher risk for hepatocellular carcinoma?","volume":"57","author":"VW Keng","year":"2012","journal-title":"J Hepatol"},{"issue":"05","key":"ref36","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/hep.32476","article-title":"Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease","volume":"76","author":"X Zhang","year":"2022","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3892\/ol.2020.11341","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study","volume":"19","author":"J Tani","year":"2020","journal-title":"Oncol Lett"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"F Carrat","year":"2019","journal-title":"Lancet"},{"issue":"09","key":"ref39","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3390\/cancers12092602","article-title":"Incidence of hepatocellular carcinoma after treatment with sofosbuvir-based or sofosbuvir-free regimens in patients with chronic hepatitis C","volume":"12","author":"E Ogawa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref40","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents","volume":"18","author":"M Mendizabal","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2543-5205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:31:54Z","timestamp":1764304314000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2543-5205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2543-5205","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"type":"print","value":"0044-2771"},{"type":"electronic","value":"1439-7803"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}